Five-year maintenance of clinical response and improvements in health-related quality of life in patients with moderate-to-severe psoriasis treated with guselkumab: Results from VOYAGE 1 and VOYAGE 2
British Journal of Dermatology — Reich K, Gordon KB, Strober BE, et al. | June 11, 2021
This study was carried out to assess physician- and patient-reported outcomes (PROs) through week 252 in VOYAGE 1 and VOYAGE 2. Researchers randomized a total of 1,829 patients at baseline to receive guselkumab 100 mg every-8-weeks, placebo, or adalimumab; placebo patients crossed-over to guselkumab at week 16. They examined effectiveness and HRQoL endpoints through week 252. Furthermore, safety was monitored through week 264. The results illustrate that in patients with moderate-to-severe psoriasis, guselkumab maintains high levels of clinical response and PRO improvement through 5 years.